LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models
Nathan A. Brooks(Eli Lilly (United States)), Raymond Gilmour(Eli Lilly (Spain)), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Zoran Ranković(St. Jude Children's Research Hospital), Marina Konopleva(Albert Einstein College of Medicine), John Strelow(Eli Lilly (United States)), Kate Newell(Eli Lilly (United States)), Jason R. Manro(Eli Lilly (United States)), Mark H. Bender(Eli Lilly (United States)), Jean‐Emmanuel Sarry(Inserm), Steven M. Chan(Princess Margaret Cancer Centre), Deepti Thete(Indiana University Bloomington), Vivian Salama(The University of Texas MD Anderson Cancer Center), Serge L. Boulet(Eli Lilly (United States)), Raquel Torres(Eli Lilly (Spain)), Rebecca Leon(Eli Lilly (United States)), Robert L. Johnson(Eli Lilly (United States)), Patric J. Hahn(Eli Lilly (United States)), Timothy P. Burkholder(Eli Lilly (United States)), Richard Romero(Eli Lilly (United States)), Xueqian Gong(Eli Lilly (United States)), Robin I. DeWalt(Arvinas (United States)), Danalyn Manglicmot. Lagutan(Eli Lilly (United States)), Rachel Cavitt(Eli Lilly (United States)), Kenneth D. Roth(Eli Lilly (United States)), Bryan Perria(Eli Lilly (United States)), Lisa Kays(Eli Lilly (United States)), Stephen Antonysamy(Eli Lilly (United States)), Sandra Gomez(Eli Lilly (Spain)), Renato A. Bauer(Eli Lilly (United States)), Paul Milligan(Eli Lilly (United States)), Anna Skwarska(Albert Einstein College of Medicine)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k